• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Streamex Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    12/30/25 6:55:07 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    false 0001530766 0001530766 2025-12-30 2025-12-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 30, 2025

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

      90025
    (Address of principal executive offices)   (Zip Code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    As reported below under Item 5.07 of this Current Report on Form 8-K, Streamex Corp. (the “Company”), held its 2025 annual meeting of stockholders on December 30, 2025 (the “Annual Meeting”), at which the Company’s stockholders approved the Fourth Amendment (the “Incentive Plan Amendment”) to the Company’s 2023 Long-Term Incentive Plan, as amended (the “Incentive Plan”), to increase the total number of shares of common stock, par value $0.001 per share (“Common Stock”), authorized for issuance under the Incentive Plan by 22,494,324 shares, to a total of 37,230,130 shares.

     

    The foregoing description of the Incentive Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Incentive Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    At the Annual Meeting at which a quorum was present, the Company held its Annual Meeting to consider and vote on the six proposals set forth below, each of which is described in greater detail in the Company’s Definitive Proxy Statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on November 20, 2025 (“Proxy Statement”). According to the certified tabulation of votes provided by Broadridge Financial Solutions, Inc., a total of 120,737,340 shares of the Company’s capital stock entitled to vote, in the aggregate (Common Stock, Exchangeable Shares (as defined in the Proxy Statement) and Series C Preferred Stock), was represented in person or by proxy at the Annual Meeting. This represented 81.21% of the 148,654,805 total outstanding shares of the Company entitled to vote. A quorum was therefore present.

     

    The matters voted upon at the Annual Meeting and the final voting results, as certified by Broadridge, were as follows:

     

    (1) The Company’s stockholders elected Morgan Lekstrom and Karl Henry McPhie to serve as Class I members of the Board of Directors of the Company (the “Board”) until the Company’s 2028 annual meeting of stockholders or upon such director’s earlier death, resignation, or removal from the Board, with the votes cast as follows:

     

    Nominee   Votes For   Votes Withheld   Broker Non-Votes
    Morgan Lekstrom   113,487,332   485,275   N/A
    Karl Henry McPhie   113,909,497   63,110   N/A

     

    The votes cast in favor of Morgan Lekstrom represented 99.57% of the votes cast.

    The votes cast in favor of Karl Henry McPhie represented 99.94% of the votes cast.

     

    (2) The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, with the votes cast as follows:

     

    For   Against   Abstain   Broker Non-Votes
    113,739,731   168,342   64,534   N/A

     

    The votes cast in favor of this proposal represented 99.85% of the votes cast.

     

    (3) The Company’s stockholders approved, on a non-binding advisory basis, three years as the frequency of advisory votes on the compensation of the Company’s named executive officers, with the votes cast as follows:

     

    For Three Years   For One Year or For Two Years   Abstain   Broker Non-Votes
    112,425,020   1,527,641   19,946   N/A

     

    The votes cast in favor of three years as the frequency of advisory votes on the compensation of the Company’s named executive officers represented 99.65% of the votes cast.

     

    Following the Annual Meeting and after due consideration of the stockholders’ vote for three years as the frequency of advisory votes on the compensation of the Company’s named executive officers, the Board determined that future advisory votes on the compensation of the Company’s named executive officers will be conducted every three years until the next advisory vote regarding the frequency of advisory votes on the compensation of the Company’s named executive officers is submitted to the stockholders or the Board otherwise determines that a different frequency for such advisory votes is in the best interests of the Company.

     

    (4) The Company’s stockholders ratified the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with the votes cast as follows:

     

    For   Against   Abstain   Broker Non-Votes
    120,701,989   26,929   8,422   0

     

    The votes cast in favor of this proposal represented 99.97% of the votes cast.

     

    5) The Company’s stockholders approved the Incentive Plan Amendment, with the votes cast as follows:

     

    For   Against   Abstain   Broker Non-Votes
    113,116,130   798,620   57,857   N/A

     

    The votes cast in favor of this proposal represented 99.29% of the votes cast.

     

    6) The proposal to approve the adjournment of the Annual Meeting, to a later date or dates as determined by the Board in its discretion, to solicit additional proxies if necessary due to insufficient votes or lack of quorum, was ultimately not required because a quorum was present. The proposal was nevertheless approved, with votes cast as follows:

     

    For   Against   Abstain   Broker Non-Votes
    119,661,751   1,054,665   20,924   0

     

    The votes cast in favor of this proposal represented 99.12% of the votes cast.

     

    No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    10.1   Incentive Plan Amendment
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      STREAMEX CORP.
         
    Date: December 31, 2025 By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. (NASDAQ: STEX) to Provide Corporate Update Webinar Highlighting 2025 Milestones and 2026 Strategic Roadmap on December 16th at 11:00am EST

    LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that it will host a corporate update webinar on December 16, 2025 at 11:00 AM EST. The event will provide shareholders with a comprehensive review of the company's 2025 achievements, an update on the GLDY launch, and an overview of the Company's strategic roadmap for 2026 and beyond. Webinar Registration To join the Streamex Investor Webinar please register at the link below: https://us06web.zoom.us/webinar/register/WN_4GJskoJHQDaPimhx7NS1uw CEO & Chairman Commentary "The second half of

    12/12/25 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Joins Solana Policy Institute in the Project Open Coalition to Advance Regulated On-Chain Trading of Real-World Assets, Including GLDY

    LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets, today announced it has joined Project Open, a landmark initiative working to establish a regulated framework for the issuance and trading of securities on public blockchains. The effort aims to unlock billions in traditional asset value through 24/7 trading, instant settlement, lower costs, and enhanced transparency for all real-world assets, while keeping the United States competitive in financial innovation. Streamex joins Solana Policy Institute united to drive the next era of compliant digital market infrastructur

    12/10/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    12/30/25 6:55:07 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    12/19/25 5:22:03 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    12/16/25 5:00:37 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gopaul Kevin Roy was granted 100,000 shares (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    1/7/26 5:05:15 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Gopaul Kevin Roy

    3 - Streamex Corp. (0001530766) (Issuer)

    12/11/25 5:15:26 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO Groenewald Ferdinand was granted 60,000 shares, increasing direct ownership by 26% to 295,000 units (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    11/21/25 4:35:48 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lekstrom Morgan Lee bought $25,060 worth of shares (7,000 units at $3.58) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    11/21/25 12:44:17 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. (NASDAQ: STEX) Joins Solana Policy Institute in the Project Open Coalition to Advance Regulated On-Chain Trading of Real-World Assets, Including GLDY

    LOS ANGELES, Dec. 10, 2025 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization of real-world assets, today announced it has joined Project Open, a landmark initiative working to establish a regulated framework for the issuance and trading of securities on public blockchains. The effort aims to unlock billions in traditional asset value through 24/7 trading, instant settlement, lower costs, and enhanced transparency for all real-world assets, while keeping the United States competitive in financial innovation. Streamex joins Solana Policy Institute united to drive the next era of compliant digital market infrastructur

    12/10/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors

    LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced the appointment of Kevin Gopaul, global financial executive and pioneering leader in the exchange-traded fund (ETF) industry, to its Board of Directors, effective immediately. Kevin brings more than 25 years of global asset management and capital markets experience, including senior leadership roles as Global Head of ETFs, Chief Investment Officer, and Canadian CEO at BMO Global Asset Management, where he helped architect and scale the firm's $100 billion ETF franchise. He currently serves

    11/18/25 8:09:24 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Launch of $100,000,000 USD GLDY Pre-Sale – A Gold-Backed Yield Generating Stablecoin Offering Institutional Yield on Physical Gold Bullion

    The launch of Streamex's $100 million USD GLDY pre-sale marks a historic opportunity for gold investors. Investing in gold is no longer just a static store of value, Streamex, through GLDY has created a yield-generating, institutional grade asset designed to offer both spot gold exposure and yield paid in additional ounces of physical gold bullion.  Key Highlights Gold Price Exposure and Gold-Denominated Distributions: GLDY is designed to combine audited physical bullion holdings with yield from institutionally managed gold leases sourced through Monetary Metals. GLDY seeks to provide exposure to the price of gold while targeting periodic distributions paid in additional ounces of gold.Rev

    11/10/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care